Pharming Group has nominated Fabrice Chouraqui as the successor to CEO Sijmen de Vries. His appointment will be subject to approval at an Extraordinary General Meeting of Shareholders (EGM).
Upon his appointment, Chouraqui will join the Board of Directors, while De Vries will step down as CEO. To ensure a smooth transition, De Vries will remain as a strategic advisor until December 31, 2025.
Richard Peters, Chairman of the Board of Directors, highlighted the expertise Chouraqui brings to Pharming:
“Fabrice is a highly experienced leader in the international pharmaceutical and biotechnology sectors. He brings extensive global expertise across the entire biopharmaceutical value chain, which will support Pharming in its next phase of growth.”
Chouraqui has held senior leadership roles at Novartis and Bristol-Myers Squibb, bringing a wealth of industry knowledge to Pharming.
With this appointment, Pharming reinforces its commitment to continuity and international expansion in the biotech sector.
VarmX has received IND approval for its Phase 3 trial of VMX‑C001, a recombinant factor X variant designed to neutralize FXa‑inhibiting anticoagulants during emergency surgery. Backed by robust Phase 1 data and boosted by a €15 million EIC investment, this step positions VMX‑C001 to meet a gap in urgent haemostasis care.
𝗛𝗼𝘄 𝗱𝗼 𝘄𝗲 𝘁𝘂𝗿𝗻 𝘀𝗰𝗶𝗲𝗻𝘁𝗶𝗳𝗶𝗰 𝗸𝗻𝗼𝘄𝗹𝗲𝗱𝗴𝗲 𝗶𝗻𝘁𝗼 𝗿𝗲𝗮𝗹 𝘀𝗼𝗹𝘂𝘁𝗶𝗼𝗻𝘀, 𝗳𝗮𝘀𝘁𝗲𝗿, 𝘀𝗺𝗮𝗿𝘁𝗲𝗿, 𝗮𝗻𝗱 𝘁𝗼𝗴𝗲𝘁𝗵𝗲𝗿? That’s the question Key Region Leiden is working to answer. Launched on July 7 at Leiden...
Peter Lindenburg winnaar VUURVLIEGEN tijdens Dutch Bio Science Week Den Haag, 4 juli 2025 – Bijna 130 leerlingen van vier basisscholen uit de Leidse regio hebben onderzoeker...